Trichloroethylene

CASRN 79-01-6

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (63 pp, 520 K) last updated: 09/28/2011

RfD (mg/kg-day) System Basis POD Composite UF Confidence
5 x 10-4 (Chronic)* Multiple* Multiple* Multiple* Multiple* Multiple*
* System-specific RfDs information used to establish RfD

Reference Concentration for Inhalation Exposure (RfC) (PDF) (63 pp, 520 K) last updated: 09/28/2011

RfC (mg/m3) System Basis POD Composite UF Confidence
0.002 (Chronic)* Multiple* Multiple* Multiple* Multiple* Multiple*
* System-specific RfCs information used to establish RfC

Cancer Assessment


Weight of Evidence for Cancer (PDF) (63 pp, 520 K) last updated: 09/28/2011

WOE Characterization Framework for WOE Characterization
Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Following U.S. EPA (2005b) Guidelines for Carcinogen Risk Assessment, TCE is characterized as "carcinogenic to humans" by all routes of exposure.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (63 pp, 520 K)

Oral Slope Factor: 4.6 x10 -2 per mg/kg-day
Extrapolation Method: PBPK model-based route-to-route extrapolation of the inhalation unit risk estimate for kidney cancer with a factor of 5 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk
Tumor site(s): Hematologic, Hepatic, Urinary
Tumor type(s): Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors (Charbotel et al., 2006 EPA, 2011 Raaschou-Nielsen et al., 2003)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (63 pp, 520 K)

Inhalation Unit Risk: 4.1 x10 -6 per µg/m3
Extrapolation Method: Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk
Tumor site(s): Hematologic, Hepatic, Urinary
Tumor type(s): Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors (Charbotel et al. 2006 EPA, 2011 Raaschou-Nielsen et al., 2003)


Organ/System-Specific RfDs:

System Basis RfD (mg/kg-day) POD UF Confidence
Developmental, Cardiovascular Increased fetal cardiac malformations in Sprague-Dawley rats 5.1 x 10-4 BMDL01 (HED99): 0.0051 mg/kg-day 10 Medium
Immunological Decreased thymus weight in female B6C3F1 mice 4.8 x 10-4 LOAEL (HED99): 0.048 mg/kg-day 100 Medium/High
Immunological, Developmental Decreased plaque-forming cell (PFC) response, increased delayed-type hypersensitivity in B6C3F1 mice 3.7 x 10-4 LOAEL: 0.37 mg/kg-day 1000 Medium/High

Organ/System-Specific RfCs:

System Basis RfC (mg/m3) POD Composite UF Confidence
Developmental, Cardiovascular Increased fetal cardiac malformations in Sprague-Dawley rats 0.0021 BMDL01 (HEC99): 0.021 mg/m3 10 Medium
Immunological Decreased thymus weight in female B6C3F1 mice 0.0019 LOAEL (HEC99): 0.19 mg/m3 100 Medium/High

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.